In search of biological marker in multiple sclerosis (MS), total-tau and phospho-tau (Thr181) concentrations were established in CSF and serum of 78 patients with MS, using commercially available kits. Serum and CSF concentrations of IgG, IgM, and albumin were assayed simultaneously to calculate quotients and indices of intrathecal synthesis. Serum t-tau detection was strikingly low (23.1%); therefore, this factor was excluded from further analysis. Serum p-tau levels did not correlate with any of indices or quotients. Unexpectedly, CSF t-tau and p-tau showed an inverse relation with MSSS and EDSS, which has not been published elsewhere. Our results do not support utility of serum t-tau and p-tau as surrogate markers for MS.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. Historically, MS was believed to involve only the myelin sheath of neuronal axons. Growing evidence, however, indicates an important role for axonal pathology, and histological studies confirm that axonal damage occurs in early stages of the disease [1] . The importance of axonal damage in MS has led to an extensive search for surrogate markers and scales that might help predict disease course, monitor its activity, and direct therapeutic decisions. An algorithm developed in 2005, the Multiple Sclerosis Severity Scale (MSSS) [2] allows assessment of disease severity by combination of single Expanded Disability Status Score (EDSS) [3] and disease duration. The latest article [4] confirms the role of MSSS in assessment of disease severity over time. As MS course is in most cases unpredictable, there is constant need for reliable surrogate markers and tau protein represtents an interesting possibility.
Tau is a microtubule-associated protein that plays an important role in the development of neuronal cells and maintaining the unique shape of neuronal processes. The first description of tau comes from pioneer work by Weingarten [5] , who reported the protein that promoted microtubule assembly in vitro. Tau is restricted almost exclusively to neurons and predominates in their axonal processes [6] . By stabilizing of microtubule polymers, the tau protein enables formation of axons and therefore is an important factor influencing polarization of neurons and axonal transport. The tau gene is located on chromosome 17. There are six isoforms of tau (with molecular weight of 55-74 kD) produced by alternative splicing of nuclear RNA [7] . In the course of number of diseases, tau may be released from intracellular milieu and enter the brain parenchymal compartment and move continuously into the cerebrospinal fluid (CSF). Increased levels of tau have previously been described in CSF in the course of Alzheimer disease (AD) [8] , Creutzfeldt-Jakob disease [9] , meningoencephalitis [10] , ischaemic stroke [11] , and closed head trauma [12] , whereas conflicting results can be found in respect to multiple sclerosis. Tau is regarded as a phosphoprotein, and phosphorylation is one of the main factors influencing both its physiological and pathological role [13] . During development and maturation of neurons, phosphorylation of tau decreases. This process augments its affinity to bind microtubules. Conversely, pathological extensive phosphorylation decreases tau affinity to bind microtubules and promotes formation of the insoluble neurofibrillary tangles that are a histological hallmark of many neurodegenerative disorders, e.g., AD, corticobasal-degeneration, Pick disease, and progressive supranuclear palsy [14] .
Until the present, studies have concentrated on alterations of total-tau (t-tau) and phospho-tau (p-tau) levels in CSF. There are few reports concerning changes in the above-mentioned proteins in serum [15, 16] . The aim of our study was to investigate concentrations of t-tau and p-tau in the CSF and serum of patients with multiple sclerosis. Secondly, we planned to correlate these results with clinical scores and indices of blood-brain barrier (BBB) dysfunction, as well as with intrathecal synthesis of IgG and IgM. Our hope was to use serum tau as an easy accessible marker of disease activity in multiple sclerosis.
Material and Methods
Blood and CSF samples were collected from 78 patients with multiple sclerosis diagnosed according to the revised McDonald criteria [17] . The male to female ratio was 37:41. Patients were categorized as having a relapsing-remitting (RR) course in 57 (male:female, 23:33) cases and secondary progressive (SP) course in 21 cases (male:female, 14:8). Age, duration of disease, EDSS score [3] , and global MSSS [2] scores are given in Table 1 and Table 4 . This study was approved by Local Ethics Committee of the Medical University of Lublin. Patients gave their informed consent to participate in the study and samples were drawn as a part of a routine neurological workup in hospital setting.
Blood samples were collected in polypropylene tubes and completely coagulated. Afterwards they were centrifuged at 5000 g for 10 minutes. Clear serum was frozen at -80º C and stored for further assays. Lumbar punctures were performed in the morning to avoid diurnal variations in protein concentrations. A spinal catheter was introduced through the L3/L4 or L4/L5 interspace, and 5 mL of clear CSF was drawn. Samples were then centrifuged at 5000 g for 10 minutes and frozen in polypropylene tubes at -80º C for further examination. Samples were thawed just prior to ELISA or immunonephelometric procedures.
Total-tau (t-tau) and phospho-tau (p-tau) concentrations were assayed at room temperature; kits were brought to the laboratory just before the assays were performed. Total-tau concentrations were assayed in duplicate samples with the commercially available INNOTEST® hTAU Ag kit from Innogenetics (Ghent, Belgium) using the sandwich ELISA method. The assay was designed to detect both phosphorylated and non-phosphorylated tau residues. The lowest detection threshold for total-tau was 60 pg/mL. Phospho-tau concentrations were assayed in duplicates with commercially available INNOTEST® PHOSPHO-TAU (181P) from Innogenetics (Ghent, Belgium) using the ELISA sandwich method. The assay was designed to detect only phosphorylated on threonine 181 forms of tau protein. The lowest detection threshold was 15.6 pg/mL. For both assays, the absorbance was measured with spectrophotometer at 450 nm. The standard blank was a sample of the diluent alone. Intraassay variability was <10%. T-tau and p-tau were assayed by an independent operator following instructions provided in the kit inserts.
Albumin and immunoglobulins concentrations in CSF and serum were measured by an independent operator using an immunonephelometric method in the Behring Nephelometer 100 System. The albumin quotient (Qalb) was calculated as CSF alb/serum alb; the IgG quotient (Q IgG)= CSF IgG/ serum IgG; IgM quotient (Q IgM)=CSF IgM/serum IgM; IgG index= (CSF IgG/serum IgG)/(CSF alb/serum alb); and IgM index= (CSF IgM/serum IgM)/(CSF alb/serum alb). Qalb and intrathecal immunoglobulins quotients were then incorporated to Reibergrams [18] in order to check if intrathecal Ig synthesis was present.
Statistical analysis
Values below the detection level were not included in further analyses. Values exceeding 2*SD (standard deviation) in the probability density function were rejected as outliers and were not included in statistical analyses. Table 3 . Summarized results in patients with MS (continued).
We chose to use the 2*SD range to ensure homogeneity of the study population. Normality was assessed using the D'Agostino-Pearson test. Since normality could not be assumed for the majority of variables, relations between variables were calculated as the Spearman correlation coefficient (r) and linear regression coefficient (r 2 ) with 95% CI. Group comparisons were performed with the Mann-Whitney nonparametric test. P<0.05 was regarded significant. All statistical calculations were accomplished with GraphPad Prism 5.01. Figure 1C ; Figure 1D ).
Results
After pooled results were split, separate analysis of the RR and SP patient groups showed that the previously described relations were not maintained in the RR group. However, a negative correlation with EDSS and MSSS remained for CSF p-tau in SP patients. For 
Discussion
Current studies have yielded conflicting results concerning role of tau protein in CSF of MS patients. There are group of studies reporting CSF tau levels in MS similar to controls [19] [20] [21] . On the other hand, some papers report increased CSF tau levels in MS compared with normal subjects [22] [23] [24] [25] . Increased t-tau concentration in the course of MS can be explained by axonal damage [26] Table 4 . Significant differences in the study population with respect to MS type.
Figure 1. Linear regression line with 95% CI band for CSF tau and EDSS and MSSS. Minimal values on x axis are defined as detection threshold
for phospho-tau (i.e. 15.6 pg/ml) and total-tau (i.e. 60.0 pg/ml).
in the aggressive, rapidly progressive type of the disease, tau protein undergoes abnormally enhanced phosphorylation, with formation of insoluble tau varieties [27, 28] . On the basis of previous studies, we designed our research without a control group. The reason for this decision was to avoid multiplying conflicting results and to avoid adding further inconsistency to the available reports. Despite that, we planned to correlate tau protein levels with clinical scores and indices of intrathecal Ig synthesis and evidence of BBB damage to find a rationale supporting the use of these assays in predicting an unfavorable MS prognosis. Tau protein is confined mainly in neuronal axonal processes. Detection of increased tau concentration in CSF is a result of neuronal damage, as is present in acute conditions e.g., stroke, closed head injury, and spongiform encephalopathy ,as well as in chronic diseases (e.g., Alzheimer disease). Conflicting results concerning tau concentrations in MS probably result from variability in the MS course and the inability to include homogenous populations.
A few current clinical studies address issue of t-tau and p-tau detection in the serum in MS patients [15] and in healthy subjects [16] . Protein derived from central nervous system can be detected in serum, but according to Reiber's work, its concentration is apparently 10-fold lower compared to that is CSF. One of the explanations for this phenomenon is leakage of molecules via a disturbed blood-brain barrier (BBB) consistent with the protein gradient. Tau concentration in CSF, similarly to other neuronal or glial proteins, decreases along CSF pathways from cerebral ventricles to the lumbar region. An increased Qalb (index of slow CSF turnover) does not influence tau concentration in CSF. In our study, neither t-tau or p-tau (in CSF and serum) correlated with Qalb, which is in agreement with Reiber's work. On the other hand, in most of our patients, there was no apparent BBB breakdown. Only in 27 patients was Qalb higher than 6.5 x10 -3 , the upper limit for patients aged 16-40 years; in 14 patients Qalb exceeded 9 x10 -3 , which is the limit for patients over age 60 [29] .
Strikingly low detection of t-tau in serum probably results from its minute penetration through BBB into serum compartments. According to Reiber's paper [16] , t-tau concentration in serum displays a large variation, from below 10 pg/mL to above 100 pg/mL. Surprisingly, serum p-tau was detected much more frequently. One reason is clear: the low sensitivity of the t-tau assay we used. To improve t-tau detection it would be beneficial to prepare reagents with higher anti-tau antibodies concentration (reducing the reagent volume to 1/3) and increasing the sample volume threefold, as was suggested previously [16] . Another explanation for the low t-tau detection despite satisfactory p-tau detection in serum could be disturbed antibody binding. The first monoclonal antibody in t-tau assay is AT120, which binds to the microtubule-binding domain located close to the C-terminal ending. The second step relies on two specific monoclonal antibodies, the HT7-N-terminal ending and the BT2-proline rich region. P-tau assay engages HT7, as mentioned previously, and AT270, in both, binding to the N-terminal part of the protein (including the first 150 amino acids). Tau released into serum compartment might undergo enzymatic processing and the C-terminal part could be lost. Evidence of enzymatic cleavage of tau protein in serum after head injury has been reported [30] . Cleaved tau (C-tau) detected in serum had a smaller molecular weight compared with native tau. The C-tau lacked N-terminal as well as the C-terminal ending, which was proved using selective antibodies assays. It is possible that tau entering serum compartments is enzymatically cleaved, loses its C-terminal part, and consequently the first step of t-tau assay becomes unfeasible even though p-tau is still efficiently detected. On the other hand, in a previously published study [31] , serum tau immunoreactivity detection in patients with dementia was approximately 20% (similar to our results) but after gel filtration peak reactivity was found in the 160kD fraction. This indicated an unexpected high molecular weight, and suggested the existence of tau-like molecules or polymers of lowmolecular weight tau. The final conclusion related to tau proteins detected in serum in our study could be drawn only after its molecular weight is ascertained.
The unexpected relation between CSF t-tau and p-tau and EDSS and MSSS has not been reported in any previous published study. There is evidence of progressive cerebral atrophy in course of MS with accumulation of disability. Neuroimaging studies proved that brain atrophy developed early in course of MS and could be seen even in CIS patients that progressed to MS. Moreover, brain atrophy correlated with disability [32] . Tau proteins are assumed to reflect neuronal damage, and after axonal injury, tau leaks into the CSF compartment. In this context, tau proteins represent severity of axonal damage and seem to correlate with disability, especially in stroke or prion diseases. On the other hand, in the stable phase of disease (e.g., during a non-active period of MS), tau protein leaks into the CSF compartment without presenting apparent signs of acute brain damage. In this context, tau concentration may be positively correlated with the number of intact neurons. Its concentration may arise from a dynamic balance between leakage into and clearance from the CSF compartment. Therefore, less disabled patients with a higher number of intact neurons release more tau than patients with pronounced brain atrophy. Interesting results come from a study by Jasperse et al. [33] , where N-acetylaspartic acid level (neuronal specific marker-NAA) in the CSF of MS patients correlated negatively with EDSS, but showed a positive relation with normalized brain volume. Continuously, CSF NAA correlated negatively with T1 and T2 lesion load. In this study, SP patients had significantly lower CSF NAA concentrations compared with RR patients. In a study by Teunissen et al. [34] , NAA levels were decreased in SP patients compared with RR. However, in this study no significant difference in tau concentration was found in respective MS types. In any case, as tau proteins are assumed to be neuronal markers, we may expect CSF tau to exhibit similar relations to NAA.
In our study, we found a significant difference in CSF t-tau between RR and SP patients, with higher concentrations in RR group. Patients in RR stage of MS are generally less disabled compared with SP patients. The higher concentration of tau in CSF of the RR group may be due to a predominating chronic inflammatory response affecting brain tissue, leading to neuronal transsection. The hallmark of the SP stage is neurodegeneration, and atrophied brain tissue may have lower potential to release tau into CSF because of the lower number of intact neurons [35] . This assumption is supported by our analysis that showed significant negative correlation of CSF p-tau with EDSS and MSSS in SP patients, but a lack of such correlation in the RR group. Unfortunately, we did not find any relation with respect to CSF t-tau, but this result can probably be attributed to the lower detection of CSF t-tau that resulted from an insufficient sample size.
In a study by Ott et al. [36] , ventricular volume was negatively associated with CSF t-tau and p-tau in patients with AD. This results support our assumption that CSF tau protein concentration reflects total brain volume.
To the contrary, in patients with mild cognitive impairment and AD, CSF t-tau and p-tau181 correlated inversely with whole brain volume [37] . Similar relations are described in a study by Tosun et al. 2010 [38] , where regional brain atrophy, in particular the lower volume of caudate nucleus as well as parieto-temporal areas atrophy was associated with increase in t-tau and p-tau181 concentrations in CSF. These studies are devoted to AD patients and presumably examine a different type of pathology, which is relatively similar in the whole spectrum from mild cognitive impairment to dementia. To the contrary, in the course of MS we confronted with variable types of pathology, depending on the clinical presentation. In the relapsing-remitting stage, inflammatory response predominates. In later stages of secondary progressive MS, the major role is assumed by neurodegenerative mechanisms.
An interesting hypothesis presented by Teunissen et al. [34] , drawn on the basis of NAA, neurofilament light and heavy chain analysis, suggests that different markers may have a variable value in the course of MS. The respective marker utility may depend upon the predominating pathological mechanism. This is probably also true for tau protein. Given the conflicting results on tau studies in MS, we suspect that this marker is not equally useful in all MS stages. Based on our results, CSF tau may be useful in later stages of MS as tau concentration decreases along with cumulative disability (as expressed in the EDSS score).
Finally, it should be stressed that calculations based on CSF protein measurements are vulnerable to extreme results. It is necessary to include a homogenous population, otherwise results are biased towards outliers. In our study, special care was taken to exclude outliers, which can be easily seen in Figure 1 .
Conclusions
The results of our study do not support a role for either serum p-tau or t-tau as a surrogate marker in MS. The unexpected negative correlation of CSF t-tau and p-tau with motor disability (in terms of EDSS) and disease severity (MSSS) suggests that tau pathology in MS is more complex and depends on disease stage. Different results obtained in previously published studies most probably reflect the inability to gather comparable groups of patients. As the clinical course of MS is in most cases unpredictable, tau concentrations are to a variable extent related to acute brain damage during relapse, chronic inflammatory processes, and finally, neurodegeneration.
